Milestone Pharmaceuticals... (MIST)
1.26
0.10 (8.62%)
At close: Apr 24, 2025, 3:59 PM
1.29
2.75%
Pre-market: Apr 25, 2025, 04:57 AM EDT
Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.
The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Milestone Pharmaceuticals Inc.
| Country | CA |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Joseph G. Oliveto M.B.A. |
Contact Details
Address: 1111 Dr. Frederik-Philips Boulevard Montreal, QC CA | |
| Website | https://www.milestonepharma.com |
Stock Details
| Ticker Symbol | MIST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001408443 |
| CUSIP Number | 59935V107 |
| ISIN Number | CA59935V1076 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph G. Oliveto M.B.A. | Chief Executive Officer, President & Director |
| Amit Hasija | Chief Financial Officer & Executive Vice President of Corporate Development |
| Jeffrey Nelson | Chief Operating Officer |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
| Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board |
| Jeff Moore | Vice President of Sales |
| Kim Fox | Vice President of Communications |
| Roshan Girglani | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 424B5 | Filing |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 13, 2025 | S-8 | Filing |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |